Day One Biopharmaceuticals announced the sale of its Priority Review Voucher (PRV) for $108 million to an undisclosed buyer. The company received the PRV following the FDA accelerated approval of OJEMDA™ (tovorafenib). The sale is a significant step for Day One, providing non-dilutive capital to strengthen its balance sheet and support the launch of OJEMDA and ongoing clinical development efforts. The Rare Pediatric Disease Priority Review Voucher Program supports initiatives for rare pediatric diseases, encouraging the development of new treatments. A portion of the proceeds from the sale will be used to fulfill obligations to Viracta Therapeutics, Inc. Day One Biopharmaceuticals is committed to redefining cancer treatment possibilities for patients of all ages, with a focus on pediatric cancer therapies like tovorafenib (OJEMDA) and pimasertib.
Day One Biopharmaceuticals Sells Priority Review Voucher for $108M, Strengthens Balance Sheet
Date:
Updated: [falahcoin_post_modified_date]
More like thisRelated
Revolutionary Small Business Exchange Network Connects Sellers and Buyers
Revolutionary SBEN connects small business sellers and buyers, transforming the way businesses are bought and sold in the U.S.
District 1 Commissioner Race Results Delayed by Recounts & Ballot Reviews, US
District 1 Commissioner Race in Orange County faces delays with recounts and ballot reviews. Find out who will come out on top in this close election.
Fed Minutes Hint at Potential Rate Cut in September amid Economic Uncertainty, US
Federal Reserve minutes suggest potential rate cut in September amid economic uncertainty. Find out more about the upcoming policy decisions.
Baltimore Orioles Host First-Ever ‘Faith Night’ with Players Sharing Testimonies, US
Experience the powerful testimonies of Baltimore Orioles players on their first-ever 'Faith Night.' Hear how their faith impacts their lives on and off the field.
